Last reviewed · How we verify

Tylenol with codeine — Competitive Intelligence Brief

Tylenol with codeine (Tylenol with codeine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic combination. Area: Pain Management.

marketed Opioid analgesic combination Mu opioid receptor (codeine); cyclooxygenase enzymes (acetaminophen) Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Tylenol with codeine (Tylenol with codeine) — National Center for Complementary and Integrative Health (NCCIH). Acetaminophen reduces fever and mild-to-moderate pain through inhibition of prostaglandin synthesis, while codeine is an opioid agonist that enhances pain relief through central nervous system depression.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tylenol with codeine TARGET Tylenol with codeine National Center for Complementary and Integrative Health (NCCIH) marketed Opioid analgesic combination Mu opioid receptor (codeine); cyclooxygenase enzymes (acetaminophen)
BENZHYDROCODONE BENZHYDROCODONE marketed Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways 2018-01-01
Codeine/acetaminophen Codeine/acetaminophen Montefiore Medical Center marketed Opioid analgesic combination Mu-opioid receptor (codeine); COX enzymes (acetaminophen)
hydrocodone/APAP hydrocodone/APAP VA Office of Research and Development marketed Opioid analgesic combination Mu opioid receptor (hydrocodone); COX inhibitor (acetaminophen)
Morphine-Promethazine Morphine-Promethazine Tel-Aviv Sourasky Medical Center marketed Opioid analgesic combination Mu-opioid receptor (morphine); H1 histamine receptor (promethazine)
metoprolol plus morphine metoprolol plus morphine Sahlgrenska University Hospital marketed Beta-blocker plus opioid analgesic combination Beta-1 adrenergic receptor; mu-opioid receptor
dexketoprofen trometamol + tramadol hydrochloride dexketoprofen trometamol + tramadol hydrochloride Kavaklıdere Umut Hospital marketed NSAID + opioid analgesic combination COX-1/COX-2 (dexketoprofen); mu-opioid receptor, norepinephrine transporter, serotonin transporter (tramadol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic combination class)

  1. VA Office of Research and Development · 3 drugs in this class
  2. Rothman Institute Orthopaedics · 2 drugs in this class
  3. Labopharm Inc. · 2 drugs in this class
  4. University of Rochester · 2 drugs in this class
  5. Montefiore Medical Center · 2 drugs in this class
  6. Maastricht University Medical Center · 2 drugs in this class
  7. Henry Ford Health System · 1 drug in this class
  8. Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
  9. Albert Einstein College of Medicine · 1 drug in this class
  10. Johnson & Johnson Taiwan Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tylenol with codeine — Competitive Intelligence Brief. https://druglandscape.com/ci/tylenol-with-codeine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: